Sagir Pharmaceuticals Ltd |
Registered Number:14573672 |
For the year ended 31 January 2025
England and Wales
Unaudited Financial Statements
For the year ended 31 January 2025
Sagir Pharmaceuticals Ltd
Contents Page
1
Statement of Financial Position
2 to 4
Notes to the Financial Statements
Sagir Pharmaceuticals Ltd
Statement of Financial Position
2024
2025
Property, plant and equipment |
1,639
890
2
1,639
890
Trade and other receivables |
1,700
-
3
2,690
Cash and cash equivalents |
20
20
4,390
Trade and other payables: amounts falling due within one year |
(4,920)
-
4
(530)
20
Net current assets
Total assets less current liabilities |
1,659
360
Trade and other payables: amounts falling due after more than |
one year |
-
(1,590)
5
-
372
Provisions for liabilities |
69
Net assets
732
5
5
64
727
69
732
Shareholders' funds
For the year ended 31 January 2025 the company was entitled to exemption from audit under Section 477 of the Companies Act 2006 relating to small companies. |
The members have not required the company to obtain an audit of its financial statements for the year ended 31 January 2025 in accordance with Section 476 of the Companies Act 2006 |
The director acknowledges his responsibilities for:a) ensuring that the company keeps proper accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and |
b) preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each |
financial year and of its profit or loss for each financial year in accordance with the requirements of Section 394 and 395 and |
which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as |
applicable to the company. |
In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered. |
The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime. |
These financial statements were approved and authorised for issue by the Board on 23 June 2025 and were signed by: |
1 of 4
For the year ended 31 January 2025
Sagir Pharmaceuticals Ltd
Statement of Financial Position Continued
The notes form part of these financial statements |
2 of 4
For the year ended 31 January 2025
Sagir Pharmaceuticals Ltd
Notes to the Financial Statements
Statutory Information
Sagir Pharmaceuticals Ltd is a private limited company, limited by shares, domiciled in England and Wales, registration number |
14573672. |
107 Uplands Road
Woodford Green
London
IG8 8JP
The presentation currency is £ sterling. |
Basis of preparing the financial statements
These financial statements have been prepared in accordance with the provisions of Section 1A of Financial Reporting |
Standard 102 ''The Financial Reporting Standard applicable in the UK and Republic of Ireland'' and the Companies Act 2006. |
The financial statements have been prepared under the historical costs convention as modified by the revaluation of certain |
assets. |
2. Property, plant and equipment |
1,186
764
422
1,395
-
1,395
1,817
764
2,581
Provision for depreciation and impairment |
296
191
105
Charge for year
646
191
455
942
382
560
1,257
382
1,639
317
573
890
3. Trade and other receivables |
2024
2025
-
1,700
3 of 4
For the year ended 31 January 2025
Sagir Pharmaceuticals Ltd
Notes to the Financial Statements Continued
4. Trade and other payables: amounts falling due within one year |
2024
2025
Taxation and social security |
-
4,920
5. Trade and other payables: amounts falling due after more than one year |
2024
2025
1,590
-
6. Average number of persons employed |
During the year the average number of employees was 2 (2024 : 2)
4 of 4